SCHEMBL6503765

SCHEMBL6503765

C(=N/Nc1nc2nonc2nc1Nc1ccccc1)\c1cc2ccccc2o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BIRC5 O15392 1/20 0.42
MAPT P10636 8/20 0.38
SMN1; SMN2 Q16637 6/20 0.38
TP53 P04637 5/20 0.38
POLB P06746 2/20 0.38
CYP2A6 P11509 1/20 0.37
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
DDX3X O00571 2/20 0.35
CTDSP1 Q9GZU7 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
GAA P10253 4/20 0.33
CCR2 P41597 1/20 0.33
CCR5 P51681 1/20 0.33
RECQL P46063 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
NPC1 O15118 2/20 0.32
PKM P14618 2/20 0.32
RAB9A P51151 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6435778 0.91 MAPT (0.47) BIRC5MAPTSMN1; SMN2TP53POLB
SCHEMBL6435783 0.91 MAPT (0.47) BIRC5MAPTSMN1; SMN2TP53POLB
SCHEMBL6415384 0.87 MAPT (0.40) BIRC5MAPTSMN1; SMN2TP53POLB
SCHEMBL6415379 0.87 MAPT (0.40) BIRC5MAPTSMN1; SMN2TP53POLB
SCHEMBL6415960 0.85 MAPT (0.41) BIRC5MAPTSMN1; SMN2TP53POLB
SCHEMBL6415964 0.85 MAPT (0.41) BIRC5MAPTSMN1; SMN2TP53POLB
SCHEMBL6414183 0.84 MAPT (0.40) BIRC5MAPTSMN1; SMN2TP53POLB
SCHEMBL6414195 0.84 MAPT (0.40) BIRC5MAPTSMN1; SMN2TP53POLB
SCHEMBL3055383 0.80 GAA (0.49) BIRC5MAPTSMN1; SMN2POLBMAOA
SCHEMBL6421048 0.80 GAA (0.49) BIRC5MAPTSMN1; SMN2POLBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 BIRC5 2525/4885MAPT 4420/4885SMN1; SMN2 4369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.